SCHEMBL8015355

SCHEMBL8015355

CCC(O)CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 6/20 0.63
TNF P01375 4/20 0.63
PDE4A P27815 2/20 0.63
PDE4B Q07343 2/20 0.63
PDE4C Q08493 2/20 0.63
PDE4D Q08499 2/20 0.63
USP2 O75604 1/20 0.63
LMNA P02545 1/20 0.63
CYP1A2 P05177 1/20 0.63
TSHR P16473 1/20 0.63
NFKB1 P19838 1/20 0.63
ACHE P22303 1/20 0.63
PMP22 Q01453 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
RXFP1 Q9HBX9 1/20 0.63
CHIT1 Q13231 1/20 0.55
CHIA Q9BZP6 1/20 0.55
ADORA2A P29274 1/20 0.53
AKR1B1 P15121 1/20 0.53
GLA P06280 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27347024 0.99 ADORA2B (0.65) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6778295 0.99 ADORA2B (0.65) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6778554 0.95 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL9293740 0.92 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8072448 0.92 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL9294827 0.92 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6785565 0.92 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8077198 0.92 ADORA2B (0.62) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL8017364 0.91 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C
SCHEMBL6777335 0.91 ADORA2B (0.63) ADORA2BTNFPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
US-5804584-A USEFUL IN TREATING INDIVIDUALS HAVING A DISEASE OR TREATMENT-INDUCED TOXICITY, MEDIATED BY SECOND MESSENGER ACTIVITY CELL THERAPEUTICS, INC. (US) 1998-09-08 US disclosed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US disclosed
EP-0669825-A4 HYDROXYL-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-03 EP disclosed
US-5473070-A Cell stimulus response modulators CELL THERAPEUTICS, INC. (US) 1995-12-05 US disclosed
EP-0669825-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-09-06 EP disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed